As of Jul 21
| +0.01 / +0.67%|
The 5 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 1.00. The median estimate represents a +32.45% increase from the last price of 1.51.
The current consensus among 5 polled investment analysts is to Hold stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.